BioSpace News Archive

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its fourth quarter ended December 31, 2022.

Astria Therapeutics, Inc., a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 10,000 shares of Astria’s common stock on March 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.

Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2022.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the full year 2022.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announces that its Chief Medical Officer, Todd Hobbs, MD, will be presenting “Rencofilstat (CRV431): Update on NASH Clinical Program,” on Friday, March 3rd at the 6th Global NASH Congress held in London, England.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that Jim Corbett, Chief Executive Officer, will present at the TD Cowen 43rd Annual Health Care Conference in Boston on Tuesday, March 7, 2023, at 9:10 a.m. Eastern Time.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a panel titled, “Novel Oncology Targets” at the 43rd Annual Cowen Healthcare Conference on Tuesday, March 7, 2023 at 9:10 a.m. ET.

Alexion, AstraZeneca Rare Disease, will showcase the potential for its pioneering therapies to redefine the treatment landscape for certain rare neurological diseases at the American Academy of Neurology Annual Meeting, April 22-27, 2023.

Mirion Technologies, Inc. announced the commencement of an underwritten public offering of 9,786,153 shares of Mirion’s Class A common stock by certain selling stockholders.

Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, announced that the Company granted a non-qualified stock option and restricted stock units to Elaine O’Hara, its newly appointed Chief Strategy Officer, as a material inducement for her entry into employment with Novavax, effective as of March 1, 2023.